Fax: þ45-72263303; E-mail: anders.larsen@leo-pharma.com Sir, The finding by Laurent et al. 1 of isolates belonging to the epidemic European fusidic acid-resistant impetigo clone (EEFIC) in France is interesting as this observation is somewhat in contrast to our findings in the EPISA study. 2, 3 However, as proposed in the EPISA study by Denton et al., 2 the different proportions of patients suffering from impetigo in the UK (120/461; 26%), Ireland (49/449; 11%) and France (36/480; 7.5%) could be associated with 'cultural differences in patients seeking medical assistance'. Laurent et al.
1 also point to this explanation as the French people may prefer to consult specialists or hospitals if affected by impetigo. In the EPISA study, 25 Staphylococcus aureus isolates obtained from French impetigo patients were characterized, but in contrast to the UK and Ireland, none of these isolates belonged to the EEFIC. 2, 3 Thus, although impetigo cases may be more numerous in France than found in our study, the dissemination of the EEFIC may still be limited. The latter is confirmed by the results of Laurent et al., 1 since they only found 10 EEFIC isolates (extrapolated: 25 -50 isolates) after thorough molecular investigations on a large collection of S. aureus spanning an 8 year period and originating from hospital as well as non-hospital (community) laboratories. Sir, In a recent issue, Zhang 1 summarized the interest in animal models to study the relationship between the influenza virus and secondary pneumonias. We agree with the role of a preceding influenza infection in secondary pneumonia. 2 -4 Referring to studies by McCullers's group, 5 -7 Zhang speculated on the adherence of Streptococcus pneumoniae in the lungs after cleavage of sialic acid residues from the surface of host cells, exposing cryptic receptors to S. pneumoniae and allowing bacteria to adhere. However, he did not mention that McCullers stated in 2006, 'the receptors that pneumococcus utilizes to adhere and invade in the lung are currently unknown'.
Transparency declarations
8 As these receptors have been searched for, but not found, it is tempting to suggest that perhaps they do not exist. Thus, they cannot be a reason to predict risks in the case of the therapeutic use of a sialidase fusion protein.
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